Hikma H1 2026 core operating profit rises 9% to $405 million; revenue increases 4% to $1.7 billion

Reuters2026/08/06 06:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

H1 2026 core revenue rose 4% to USD 1.73 billion; core operating profit increased 9% to USD 405 million.
Core operating margin widened 0.9 percentage points to 23.4%; core basic EPS climbed 5% to 128 cents.
Operating cash flow increased to USD 214 million from USD 161 million; capital expenditure totaled USD 122 million.
Branded revenue grew 15% to USD 502 million; core operating profit rose 23% to USD 163 million, lifting margin to 32.5%.
Full-year guidance reiterated: group revenue growth 2% to 4% with core operating profit of USD 720 million to USD 770 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hikma H1 2026 core operating profit rises 9% to $405 million; revenue increases 4% to $1.7 billion

You may also like

Crypto prices